BREAKING
BioNTech (BNTX) Posts Q4 Loss of $-1.25/Share as Revenue Falls 23.8% YoY to $907.4M 3 minutes ago Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year 8 minutes ago Tenax Therapeutics Inc (TENX) Reports Q4 Earnings 10 minutes ago Opus Genetics Inc. (IRD) Reports FY25 Earnings 14 minutes ago Apyx Medical (APYX) Q4 Revenue Jumps 34.8% to $19.2M, Loss Narrows to $0.06/Share 20 minutes ago Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings 26 minutes ago Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates 33 minutes ago Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M 37 minutes ago Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M 41 minutes ago SuRo Capital Corp (SSSS) Reports Wider Loss Q4 Estimates by 10.0% 45 minutes ago BioNTech (BNTX) Posts Q4 Loss of $-1.25/Share as Revenue Falls 23.8% YoY to $907.4M 3 minutes ago Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year 8 minutes ago Tenax Therapeutics Inc (TENX) Reports Q4 Earnings 10 minutes ago Opus Genetics Inc. (IRD) Reports FY25 Earnings 14 minutes ago Apyx Medical (APYX) Q4 Revenue Jumps 34.8% to $19.2M, Loss Narrows to $0.06/Share 20 minutes ago Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings 26 minutes ago Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates 33 minutes ago Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M 37 minutes ago Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M 41 minutes ago SuRo Capital Corp (SSSS) Reports Wider Loss Q4 Estimates by 10.0% 45 minutes ago
ADVERTISEMENT
Breaking News

SuRo Capital Corp (SSSS) Reports Wider Loss Q4 Estimates by 10.0%

**SuRo Capital Corp Reports Wider-Than-Expected Q4 Loss**

$SSSS March 10, 2026 1 min read
NYSE
$SSSS · Earnings

**SuRo Capital Corp Reports Wider-Than-Expected Q4 Loss**

**SuRo Capital Corp Reports Wider-Than-Expected Q4 Loss**

SuRo Capital Corp (SSSS) reported Q4 2025 GAAP loss of $0.22 per share, a wider loss than the -$0.20 estimate (10.0% wider). The venture capital and business development company, which specializes in growth capital and late-stage investments in venture capital-backed private companies, missed analyst expectations for the quarter.

SuRo Capital Corp. is a venture capital, mezzanine, secondary(direct) and business development company specializing in growth capital, emerging growth, late stage and venture capital-backed private companies. The company invests in technology and innovation-focused portfolio companies.

Shares of the NASDAQ-listed firm trade under the ticker SSSS.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.

ADVERTISEMENT
ADVERTISEMENT
Tags: #SSSS